Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 JAK2 Mutation clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07886801
A Study of Ropeg-Interferon in People With Polycythemia Vera
The researchers are doing this study to find out whether it is practical (feasible) to stop treatment with ropeg-interferon (ropeg-INF) for some people with polycythemia vera (PV) with a change (mutation) in theJa nus kinase 2 (JAK2) gene, based on how their disease responds to treatment.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-03
2 states
NCT07249840
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm. The main questions it aims to answer are: * Can we enroll 12 patients with JAK2 mutations and high risk features without a myeloproliferative neoplasm on a clinical trial evaluating the drug ropeginterferon? * Is ropeginterferon safe to use in these patients? Participants will: * Receive ropeginterferon as an injection under the skin once every 4 weeks * Visit the clinic every 1-3 months for checkups and tests
Gender: All
Ages: 18 Years - Any
Updated: 2026-07-28
1 state